HeyJaredBioworld Clinical
BioWorld Clinical is a specialized news outlet focused on late-stage biopharmaceutical research, clinical development, and the business implications of drug advancement.
- Indexed articles, last 90 days
- 275
- Latest publication
- Sep 25, 2026
- Audience
- Top 5M sites
- Earliest in this view
- Jul 3, 2026
Latest articles
Biopharma money raised: Jan. 1-Sept. 24, 2026 (opens the original)
Read excerpt
Year-to-date money raised in public, private and other financings of biopharma companies.
Money raised by biopharma (opens the original)
Read excerpt
Total raised in public, private and other financings of biopharma companies, comparing 2019-2026.
Clinics: Positive CAR T data for Kyverna; mixed findings for Vistagen in SAD (opens the original)
Read excerpt
Clinical updates for biopharma and med tech, including data readouts and publications: Abbisko, AC Immune, Acadia, Alkermes, Amgen, Arcturus, Astrazeneca, Autobahn, Avalyn, Beacon, Bridgebio, Caliway, Celldex, Clywedog, Cosmo, Cue, Eledon, Field Medical, Genentech, Imunon, J&J, Kyverna, Maia, Medincell, Merck, Novo Nordisk, Ophirex, Opterion, Oruka, Otsuka, PDS, Pharming, Roche, Roivant, Sensorium, Stimcardio, Teva, Theragen, Theranica, Treace, Vertex, Viking, Vironexis, Vistagen, Xenon.
Blockbusters lift 2026 biopharma deal value to record $199B (opens the original)
Read excerpt
The value of biopharma deals has generally trended upward, despite year-over-year and month-to-month volatility. BioWorld’s records show the January-August total rose from $111.9 billion in 2019 to $186.5 billion in 2025, before reaching a record $199.2 billion in just the first eight months of 2026. The increase this year was driven by several strong months, including May ($41.9 billion), June ($34.6 billion), January ($31.2 billion) and February ($30.5 billion).
Another top IPO: Adarx’s $446M to advance clinical siRNA assets (opens the original)
Read excerpt
At $446.3 million in gross proceeds, RNA-focused Adarx Pharmaceuticals Inc.’s IPO represents the fourth largest biopharma debut for 2026, a year that is proving to be the most prolific of any year during the industry’s three-decade history.
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.